Tgtx.O
TGTX.O is a biotechnology company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases, primarily through its lead product, Tavneos (avacopan), which is approved for the treatment of ANCA-associated vasculitis.
Business. TGTX.O is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm generates revenue through product sales and is tracked by key industry metrics such as pipeline depth and research and development expenditure. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TGTX.O is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm generates revenue through product sales and is tracked by key industry metrics such as pipeline depth and research and development expenditure. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
TGTX's capital structure is characterized by a market cap of $5.53 billion and a price-to-book ratio of 8.53, indicating a premium valuation relative to its book value. The company's liquidity position is mixed, with $79.15 million in cash and equivalents but a negative net cash position after subtracting $245.65 million in long-term debt. Free cash flow of $447.02 million suggests strong cash generation, but operating cash flow is negative at -$24.77 million, signaling potential near-term operational challenges.
Profitability metrics show a return on equity (ROE) of 69.01% and a return on assets (ROA) of 42.06%, both significantly above the industry median for biotechnology firms. The company's gross margin of 83.6% (calculated from gross profit of $515.57 million on revenue of $616.29 million) is robust, but its operating margin of 19.99% is lower, reflecting high R&D and SG&A expenses typical in the sector.
Geographically, TGTX's revenue is concentrated in the United States, with no material international operations disclosed. The company's product portfolio is currently centered on Tavneos, with no other commercialized products contributing to revenue. This concentration in a single product and market increases exposure to regulatory, reimbursement, and competitive risks.
Growth trajectory is positive, with revenue of $616.29 million in the latest period. Analysts project a mean price target of $44.33, implying a 22.7% upside from the current market price of $36.10. The company's capital expenditure of -$214,000 suggests minimal investment in physical assets, consistent with a biotech firm focused on R&D rather than manufacturing infrastructure.
Risk factors include a medium liquidity rating due to the negative net cash position and a debt-to-equity ratio of 0.38. The company has a low dilution risk, with basic and diluted shares outstanding aligned at 153.09 million. No recent dilutive events are disclosed, and the risk assessment does not flag near-term dilution pressure.
Recent events include the continued commercialization of Tavneos and ongoing clinical trials for additional indications. The company has not disclosed any material regulatory or litigation risks in the latest filings, but the biotech sector is inherently subject to high R&D failure rates and regulatory uncertainty.
- TGTX's strong ROE and ROA highlight its efficient use of equity and assets, but its negative operating cash flow raises concerns about short-term liquidity.
- The company's valuation is premium, with a P/B of 8.53 and a P/E of 12.36, suggesting market confidence in its growth potential.
- Revenue concentration in a single product and market increases vulnerability to competitive and regulatory shifts.
- Analysts are optimistic, with a mean price target of $44.33 and a strong-buy rating from one of eight analysts.
- The company's low debt and high free cash flow provide flexibility for R&D investment or strategic acquisitions.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,38 |
| Revenue | —no estimate | —no estimate | 942,4M USD |
| Operating income | —no estimate | —no estimate | 265,3M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- TGTX.O Market data — financials · 2026-05-29
- TG Therapeutics Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Insider activity
- Director · Common StockOther 13 197 · 2026-01-29
- Director · Common StockOther 30 000 · 2026-01-28
- Director, CEO · Common StockOther 622 000 · 2026-01-08
- CFO · Common StockOther 90 000 · 2026-01-08
- Director · Common StockSold 5 000 @ $32,57$163K · 2025-11-24
- Director, CEO · Common StockOther 803 717 · 2025-11-05
- Director, CEO · Common StockOther 3 865 126 · 2025-11-05
- Director · Common StockSold 20 852 @ $32,24$672K · 2025-09-11
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 16.9%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 194.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 69.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 87.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 191.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 84.1%Derived (calculated)
- Net margin (FY 2025-12-31): 72.6%Derived (calculated)
- Return on equity (FY 2025-12-31): 69.0%Derived (calculated)
- Return on assets (FY 2025-12-31): 42.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.10xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.64xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 375.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -56.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 161.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 1,837.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 1,746.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 1,811.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 38.9%Derived (calculated)
- Pre-tax income (annual): USD 107.39MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 3SEC XBRL filing
- Long-term debt (annual): USD 245.65MSEC XBRL filing
- Current liabilities (annual): USD 153.76MSEC XBRL filing
- Net income (annual): USD 447.2MSEC XBRL filing